Name: Terazosin HCl Dihydrate
Brand: Selleck Chemicals
SKU: S2059
Availability: InStock
Rating: 5 (3 reviews)

Jump to

Quality Control

Batch: S205901 DMSO]26 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.97%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.97

Related Targets	AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Adrenergic Receptor Inhibitors	ICI 118551 Hydrochloride (Zenidolol) L755507 Yohimbine HCl Atipamezole Higenamine hydrochloride Noradrenaline bitartrate monohydrate Fenoterol hydrobromide Medetomidine HCl Isoprenaline L-Adrenaline

Solubility

In vitro
Batch:

DMSO : 26 mg/mL (56.53 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	459.92	Formula	C₁₉H₂₅N₅O₄.HCl.2H₂O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	70024-40-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.O.O.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	α-adrenergic receptor
In vitro	Terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner in prostate cancer cells. Terazosin suppresses prostate growth potentially via α 1-adrenoceptor-independent actions gains further support from another study documenting that Doxazosin inhibits proliferation of human vascular smooth muscle cells independently of an antagonistic effect on α1-adrenoceptor. Terazosin blocks HERG currents in Xenopus oocytes with IC50 of 113.2 mM, while Terazosin blocks HERG channel inhibition in human HEK 293 cells with IC50 of 17.7 mM. Terazosin or genistein treatment inhibits the growth of DU-145 cells in a dose-dependent manner, whereas has no effect on normal prostate epithelial cells. Terazosin results in the genistein-induced arrest of DU-145 cells in G2/M phase being overridden and an increase in apoptotic cells, as evidenced by procaspase-3 activation and PARP cleavage. Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 mM.
In vivo	Terazosin significantly inhibits vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 mM, showing that it has a more potent anti-angiogenic than cytotoxic effect. Terazosin also effectively inhibits vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 mM, respectively).
References	[1] https://pubmed.ncbi.nlm.nih.gov/10969806/ [2] https://pubmed.ncbi.nlm.nih.gov/15098086/ [3] https://pubmed.ncbi.nlm.nih.gov/19091461/ [4] https://pubmed.ncbi.nlm.nih.gov/12544352/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-01)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07796308	NOT_YET_RECRUITING	Alzheimer s Disease	Qiang Zhang	2027-08-01	PHASE2
NCT07207057	RECRUITING	Parkinsons Disease (PD)	University College, London	2025-09-12	PHASE3
NCT04760860	NOT_YET_RECRUITING	Dementia With Lewy Bodies	Qiang Zhang	2027-10	PHASE1; PHASE2
NCT07288450	NOT_YET_RECRUITING	Parkinson's Disease	Nandakumar Narayanan	2026-09-01	PHASE1; PHASE2
NCT07464028	NOT_YET_RECRUITING	Parkinson's Disease (PD)	Nandakumar Narayanan	2026-07-01	PHASE2
NCT07224269	RECRUITING	Amyotrophic Lateral Sclerosis; Adenosine Triphosphate Activities	University of Iowa	2026-08-12	EARLY_PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Terazosin HCl Dihydrate Adrenergic Receptor antagonist

Chemical Structure

Molecular Weight: 459.92